Cornish J, Tan E, Teare J et al.A meta-analysis on the influence of inflammatory bowel disease on pregnancy. Gut 56:830-837

Department of Biosurgery and Surgical Technology, St Mary's Hospital, Imperial College, 10th Floor QEQM Wing, Praed Street, London W2 1NY, UK.
Gut (Impact Factor: 14.66). 06/2007; 56(6):830-7. DOI: 10.1136/gut.2006.108324
Source: PubMed


Inflammatory bowel disease (IBD) has a typical onset during the peak reproductive years. Evidence of the risk of adverse pregnancy outcomes in IBD is important for the management of pregnancy to assist in its management.
To provide a clear assessment of risk of adverse outcomes during pregnancy in women with IBD.
The Medline literature was searched to identify studies reporting outcomes of pregnancy in patients with IBD. Random-effect meta-analysis was used to compare outcomes between women with IBD and normal controls. Patients and
A total of 3907 patients with IBD (Crohn's disease 1952 (63%), ulcerative colitis 1113 (36%)) and 320 531 controls were reported in 12 studies that satisfied the inclusion criteria.
For women with IBD, there was a 1.87-fold increase in incidence of prematurity (<37 weeks gestation; 95% CI 1.52 to 2.31; p<0.001) compared with controls. The incidence of low birth weight (<2500 g) was over twice that of normal controls (95% CI 1.38 to 3.19; p<0.001). Women with IBD were 1.5 times more likely to undergo caesarean section (95% CI 1.26 to 1.79; p<0.001), and the risk of congenital abnormalities was found to be 2.37-fold increased (95% CI 1.47 to 3.82; p<0.001).
The study has shown a higher incidence of adverse pregnancy outcomes in patients with IBD. Further studies are required to clarify which women are at higher risk, as this was not determined in the present study. This has an effect on the management of patients with IBD during pregnancy, who should be treated as a potentially high-risk group.

Download full-text


Available from: Julian P. Teare, Jan 14, 2014
  • Source
    • "Patients with active disease at the time of conception may have an increased risk of spontaneous abortion. Rates of preterm delivery, low birth weight (<2500 g), and congenital anomalies are also increased [8]. A rare but potentially fatal complication of UC is toxic megacolon. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Ulcerative colitis is an idiopathic inflammatory bowel condition whose peak incidence coincides with fertility in female patients. In pregnancy, acute fulminant colitis is rare, and, when it becomes refractory to maximum medical therapy, emergency colectomy is mandated. Over the past quarter century, there have been few reports of this rare event in the literature. We report a 26 year old primigravida female who presented with toxic megacolon during the third trimester of pregnancy, unresponsive to medical therapy. She subsequently underwent an urgent low transverse caesarean section with a total colectomy. Both mother and child made a satisfactory recovery post operatively. Although the fetus is at higher risk than the mother in such a circumstance, morbidity and mortality rates are still noticeably high for both, and therefore, prompt diagnosis is key. It is imperative that female patients planning to conceive with a known diagnosis of ulcerative colitis liaise with their obstetricians and gastroenterologists early to optimise medical treatment to prevent the development of a toxic megacolon and that conception is planned during a state of remission. Should surgical intervention become required, this can be performed with favourable outcomes for mother and child, as demonstrated in this report. Copyright © 2015. Published by Elsevier Ltd.
    International Journal of Surgery Case Reports 04/2015; 369. DOI:10.1016/j.ijscr.2015.04.033
  • Source
    • "Women with IBD have an increased risk of adverse pregnancy outcomes (odds ratio, 1.65; 95% confidence interval, 1.09-2.48) [16,17]. The main adverse outcomes are of impaired foetal growth and difficulties with maintenance of pregnancy, with a greater incidence of premature births and low birth weight infants reported in women with IBD [16]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Allopurinol is a frequently prescribed drug. In inflammatory bowel disease patients who shunt thiopurine metabolism towards more toxic and less desirable pathways, allopurinol is proving to be an effective add on therapy with good resultant disease control and less treatment side effects. As many such patients are young, the potential for pregnant women to be exposed to allopurinol is increasing. The safety of allopurinol in pregnancy is not known however. We report three cases of safe use of allopurinol in pregnancy for women with inflammatory bowel disease. This included 2 patients with ulcerative colitis and 1 patient with fistulising Crohn's disease. Allopurinol was used throughout pregnancy in all patients. All 3 pregnancies resulted in normal healthy babies born at term by Caesarean section. It is important to evaluate and document the safety of allopurinol during pregnancy, as it is finding new roles in young patients. These three cases add significantly to the very limited data on allopurinol use in pregnancy. We encourage reporting of all cases of allopurinol use in pregnant patients and suggest an allopurinol pregnancy registry to document drug exposures and outcomes.
    BMC Gastroenterology 12/2013; 13(1):172. DOI:10.1186/1471-230X-13-172 · 2.37 Impact Factor
  • Source
    • "Increased prostaglandins and cytokines are evident in the peritoneal fluid of women with endometriosis [11], suggesting an association between chronic inflammation and preterm birth [5]. This is also valid for Crohn's disease or rheumatoid arthritis, which are associated with preterm birth [12] [13]. A case–control study also showed a correlation between preterm birth and adenomyosis. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Objectives: Increased incidence of preterm birth, pregnancy-induced hypertension (PIH) and small-for-gestational-age (SGA) babies have been reported in women with endometriosis, but the study populations included women in whom a definitive diagnosis was not attainable, and women who conceived via in vitro fertilization/embryo transfer (IVF/ET), which, in itself, is a risk factor for adverse pregnancy outcome. Thus there is a lack of consensus on the effects of endometriosis on pregnancy outcome. This study compared the pregnancy outcomes of women with or without a definitive diagnosis of endometriosis on laparoscopy. Study design: Retrospective comparison of pregnancy outcomes of 108 women who underwent managed delivery of pregnancies established after laparoscopic investigation of infertility. Women with factors known to affect pregnancy outcome, such as age ≥41 years, conception via IVF/ET and multiple births, were excluded. Forty-nine of the study participants had endometriosis (En+ group) and 59 participants did not have endometriosis (En- group). Results: There were no significant differences in mean (±standard deviation) age (33±3.8 vs 33.6±4.1 years), history of miscarriage, history of preterm birth and history of PIH between the two groups. Ovulation induction was used for infertility treatment in 26.5% of the En+ group and 30.5% of the En- group, and artificial insemination was used in 30.6% of the En+ group and 32.2% of the En- group. Regarding pregnancy outcomes, no significant differences in miscarriage (18.4% vs 18.6%), subchorionic haematoma (5.0% vs 2.1%), preterm birth (7.5% vs 8.3%), PIH (15.0% vs 12.5%), caesarean section (32.5% vs 22.9%), gestational age at delivery (38.9±1.5 vs 38.8±1.7 weeks), birth weight (3013.3±480 vs 2934.5±639.5g) and SGA babies (2.5% vs 2.1%) were found between the En+ and En- groups. Placental abruption did not occur in either group. One neonate had trisomy 21 in the En+ group, and one woman had gestational diabetes in the En- group. Conclusion: Endometriosis may not affect pregnancy outcome, but there is a need for a large prospective study.
    European journal of obstetrics, gynecology, and reproductive biology 10/2013; 172(1). DOI:10.1016/j.ejogrb.2013.10.024 · 1.70 Impact Factor
Show more